ty -jour t1-用 分枝杆菌结核病治疗：更新2010 JF-欧洲呼吸杂志-Leung，C.C。Au -Rieder，H.L。Au -Lange，C.Au -Yew，W.W。Y1- 2011/03/01 UR -http：//www.qdcxjkg.com/content/37/3/3/690.abstract N2-关于潜在感染与结核分枝杆菌的潜在感染。现有的用于此疾病的免疫诊断工具具有各种局限性，最重要的是它们预测疾病的能力。在非HIV感染和HIV感染的受试者中，随机对照试验已确定了异烟肼治疗的保护性疗效6-12个月。虽然功效可能达到90％，但对延长治疗的接受和依从性却少于预期。利福平加吡唑胺2个月，尽管有效，但与非HIV感染者的肝毒性过量有关。Isoniazid Plus Rifampicin在3个月中已证明有效性，但不良反应可能比异念珠菌或利福平单一疗法更频繁。利福平单一疗法3-4个月的耐受性良好，但目前有限的功效数据限制，并且由于可能选择利福平耐药突变体而担心。 For contacts of patients with multidrug-resistant tuberculosis, expert opinions differ on whether to treat with at least two drugs or just a fluoroquinolone, and for how long. With the existing diagnostic and treatment tools, efficacy of preventive therapy does not necessarily translate into field effectiveness. A targeted approach is required to maximise cost-effectiveness. Each geographic region needs to set its own priority after taking into account available scientific data and local circumstances. ER -